Skip to main content
| News

ten23 health settles in Basel

02.09.2021

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health. As a partner, it hopes to support leading global biotech and pharma clients with the development, manufacture, and testing of injectable biopharmaceuticals.

Ten23 health has announced that it has commenced operations in Basel. Its company headquarters are located on the Rosental Mitte campus. A new working environment for 150 full-time positions is being offered over 4,000 square meters of laboratory and office space in the building that was formerly home to Elanco.

The company hopes to use its scientific competence and its “globally recognized” expertise in industry and regulations to support clients from the global biotech and pharmaceutical industries with the development, manufacture, and testing of injectable biopharmaceuticals. It is “solidly financed” through the commitment of the UK-based associated company 3i Group.

Ten23 health states that it is led by a world-class leadership team and is able to demonstrate “outstanding expertise” in the biopharmaceutical industry, pharmaceutical and analytical sciences, development, and regulatory requirements. The team headed up by CEO Prof. Dr. Hanns-Christian Mahler has “a proven track record in the field of pharmaceutical product design and development” as well as an “extensive global pharma network”.

The CEO adds: “Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development.” The aim is to enable rapid, high-quality, successful commercialization.

Richard Relyea, a Partner at 3i and a Member of the Board of Directors of ten23 health, emphasizes the holistic approach of ten23 health, saying: “We will deliver services in an engrained, fair and sustainable manner.” By investing in ten23 health, 3i intends to support “the establishment of a uniquely differentiated partner to leading global biotech and pharmaceutical customers”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

BeiGene opens European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

BeiGene opens European headquarters in Basel

BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...

Read More
The 25 Best AI Courses in the Basel Area, Germany and France
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation

The 25 Best AI Courses in the Basel Area, Germany and France

Artificial Intelligence (AI) offers numerous possible applications. But how, where and regarding which focal points can you get further training...

Read More
Engimmune Therapeutics banks 15.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Engimmune Therapeutics banks 15.5 million Swiss francs

Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies...

Read More
Bionter receives 3 million US dollars in investments
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Bionter receives 3 million US dollars in investments

Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring...

Read More
Resistell seeking to further develop test to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Resistell seeking to further develop test to combat antibiotic resistance

The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being...

Read More
Biotech startup Cimeio receives 46 million Swiss francs for cell therapy
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Biotech startup Cimeio receives 46 million Swiss francs for cell therapy

Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is...

Read More
1 2 3 55

Do you have a question? We'd like to hear from you.